Circio has entered a partnership with the TraffikGene Project to develop non-viral delivery methods for its circVec platform. The collaboration focuses on overcoming key hurdles in gene therapy by replacing traditional viral vectors with synthetic alternatives.
The partnership will begin with initial screening of peptide carriers combined with circVec vectors in vitro. Subsequent steps include lead formulation physicochemical optimization and in vivo evaluation in mouse models to assess expression kinetics, biodistribution, and delivery efficacy.
No timeline for completion or regulatory milestones has been disclosed. The agreement appears to be at a preclinical stage, with no mention of future clinical trial plans or specific designations from regulatory bodies.
Circio's circVec technology is designed to enable circular RNA-based therapies, which offer potential advantages in stability and protein expression. The partnership with TraffikGene, a consortium focused on non-viral gene delivery, could bolster Circio's position in the competitive gene therapy landscape.
Investor implications remain unclear as no financial terms were released. The success of this collaboration hinges on the ability to achieve safe and efficient delivery, a challenge that has historically plagued non-viral approaches in gene therapy.